about
Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trialsPharmacotherapy options for cataplexyWidespread hypermetabolism in symptomatic and asymptomatic episodes in Kleine-Levin syndromeFrench consensus. Hypersomnolence: Evaluation and diagnosis.HLA-DPB1 and HLA class I confer risk of and protection from narcolepsyCD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice.MEIS1 variant as a determinant of autonomic imbalance in Restless Legs Syndrome.Restless legs syndrome and cardiovascular diseases: A case-control study.Incidence, worsening and risk factors of daytime sleepiness in a population-based 5-year longitudinal study.Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patientsHypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy.Restless legs syndrome is frequent in narcolepsy with cataplexy patientsLow vitamin D in narcolepsy with cataplexy.Daytime sleepiness in Parkinson's disease: a reappraisal.Aerobic determinants of the decline in preferred walking speed in healthy, active 65- and 80-year-olds.From state dissociation to status dissociatus.Hypnotics and mortality in an elderly general population: a 12-year prospective study.Insomnia and daytime sleepiness are risk factors for depressive symptoms in the elderly.CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditionsCar Crashes and Central Disorders of Hypersomnolence: A French Study.Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness TestAltered sleep-related blood pressure profile in hypocretin-deficient narcoleptic patients.Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study.Genetics of normal and pathological sleep in humans.Excessive sleepiness is predictive of cognitive decline in the elderlyChiari malformation and sleep related breathing disorders.Prevalence and comorbidity of nocturnal wandering in the U.S. adult general population.Family history of insomnia in a population-based sample.EFNS guidelines on management of narcolepsy.Loss of the transcription factor Meis1 prevents sympathetic neurons target-field innervation and increases susceptibility to sudden cardiac deathSmoking, Alcohol, Drug Use, Abuse and Dependence in Narcolepsy and Idiopathic Hypersomnia: A Case-Control StudyNarcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated CytotoxicityFunctional impairment in adult sleepwalkers: a case-control studyExcessive daytime sleepiness and antipathogen drug consumption in the elderly: a test of the immune theory of sleep.Pain in Sleepwalking: A Clinical Enigma.Absence of NMDA receptor antibodies in the rare association between Type 1 Narcolepsy and Psychosis.Reward-based behaviors and emotional processing in human with narcolepsy-cataplexy.Impact of Astroglial Connexins on Modafinil Pharmacological Properties.Effect of psychostimulants on impulsivity and risk taking in narcolepsy with cataplexy.Insomnia in patients with neurodegenerative conditions.
P50
Q28252296-9F973ECE-5C7C-4EB1-9111-9A9622F1FC52Q28287690-8F4ECE32-E479-4FD9-9B0A-E5719CF13CDCQ28541945-09FD9C0F-E5E0-4B70-96B0-8E9A4840A885Q30241379-6B5AD281-F27B-4AC2-A016-0DC159360235Q30370632-73216ECF-D9DD-42FA-9373-95587AA0EADDQ30818202-F7DA3686-6EEE-43C3-8D29-24D67B6CB356Q30846389-6B973C67-1A18-4BE7-AEB8-66A998ECD5B7Q33605971-FFB6BBBF-5C82-431F-910B-5C1CBC92BA5AQ33683837-BC929D44-7508-4323-AEED-5FEDFD3AC306Q33685660-0A6852CF-1494-4A14-AD67-B3A9C0B277D0Q33737141-15440FE9-973D-4A9E-ADA6-090601B5BA5FQ33830950-E3FA738A-23ED-4294-81A0-58767D1EFB00Q33919832-A335A89A-FE09-44F3-8DD0-35DF3AC3327FQ34150079-453D026B-A0AB-49D1-B966-3F72DC3369B4Q34282485-CAAE392B-8C54-469E-B30C-0A8DC1B0AD2BQ34673554-82ADDD35-083A-455B-BD28-D8D3CADDC2E5Q35000200-39537EC0-13BD-4D10-A06A-45D78451B739Q35110572-844140F1-40D6-45A9-AD8C-A9E30B63D878Q35560285-FF507372-F4FA-49F6-B9AC-039253A7F6F7Q35656145-FEC2EB81-0879-4971-9BD3-191929417178Q35782418-82124C10-4CCC-402D-B489-71199BA1A940Q35812426-CE36C94C-9257-4D5E-B276-1E02F96AECB9Q35866959-1B16649A-3278-445B-B4D7-8D937D0AC2E2Q36057687-0A293FB5-8A06-4909-927F-422C236B2956Q36147041-AB2024C9-19AF-4DA2-BA87-508723FCFE29Q36172543-76DC61F2-FA61-43DD-BE79-266E0A890ECDQ36307084-631446EF-AE0C-4A1A-81B8-0454345486CCQ36511624-2BDAD19B-6EDE-4402-82BE-B64AF0095327Q36598957-AE2163DB-F670-4AB7-A81D-27C51A2F0727Q36599424-3735D178-8D17-4B76-B35C-410EE19AAF22Q36606342-07B45CE6-123F-487D-A8AC-3936427B8DE3Q36606370-E333C890-B337-46D2-8904-35A159666917Q36607999-62C3C822-F3A2-4767-90E5-055447708F52Q36709088-1F2DD0A8-F035-4506-A6E7-17DF938508BDQ36744143-29DA648B-4138-4F18-9A87-78E8A6F91655Q36865000-946A0526-865F-4F8A-B620-208A87BB4068Q36868678-37AC313F-AE55-4DDF-A189-7FC8F1D3633CQ36890146-DD28C415-CDE2-49B9-B9F8-6F8B7CB3CB86Q37081682-A5975538-41B2-4C71-A937-A629595A81A0Q37112212-FC70B0AA-F40A-4C39-8534-98B96F18F54F
P50
description
researcher ORCID: 0000-0003-0683-6506
@en
wetenschapper
@nl
name
Yves Dauvilliers
@ast
Yves Dauvilliers
@en
Yves Dauvilliers
@es
Yves Dauvilliers
@nl
type
label
Yves Dauvilliers
@ast
Yves Dauvilliers
@en
Yves Dauvilliers
@es
Yves Dauvilliers
@nl
altLabel
yves Dauvilliers
@en
prefLabel
Yves Dauvilliers
@ast
Yves Dauvilliers
@en
Yves Dauvilliers
@es
Yves Dauvilliers
@nl
P106
P31
P496
0000-0003-0683-6506